Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo

Overexpression of adenosine triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2) in cancer cells is known to cause multidrug resistance (MDR), which severely limits the clinical efficacy of chemotherapy. Currently, there is no FDA-approved MDR modulator for clinical use. In this study, r...

Descripció completa

Dades bibliogràfiques

Autors principals:	Fanpu Zeng, Fang Wang, Zongheng Zheng, Zhen Chen, Kenneth Kin Wah To, Hong Zhang, Qian Han, Liwu Fu
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2020-05-01
Col·lecció:	Acta Pharmaceutica Sinica B
Matèries:	Rociletinib Tyrosine kinase inhibitor Multidrug resistance ABCG2 ATPase
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2211383519310743
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!